There is no evidence to support or refute the proposed use of β-agonists for analgesia in patients with renal colic. Given the biological plausibility and existing literature base, clinical trials investigating the use of β-adrenoreceptor agonists in the acute setting for treatment of the pain associated with renal colic are recommended.
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BACKGROUND Description of the condition
The lifetime incidence of renal calculi (kidney stones) is ∼12% in males and 6% in females 1 with a peak between 40 and 60 years of age. 2 Renal colic is the pain experienced by a patient when a renal calculus causes partial or complete obstruction of part of the renal outflow tract. Pain in renal colic is caused by ureteric spasm with increased peristalsis around the stone and dilation of the proximal urinary tract. Local irritation with prostaglandin release and inflammation further increases the renal pelvic pressure. 3 The clinical need that prompted this systematic review Current analgesic regimes, usually involving a non-steroidal anti-inflammatory drug (NSAID)±an opiate, 2 are often suboptimal; in some studies, less than half of the patients achieve complete pain relief within an acceptable time frame and a large proportion of patients require rescue analgesia within 4 hours. Additionally, side effects (especially vomiting) are relatively common with opioid analgesia. 4 Description of the intervention β-Adrenoreceptor agonists (β-agonists) such as salbutamol/albuterol (a selective β 2 -agonist 5 in common use) are used as a treatment for acute exacerbations of asthma in both its nebulised and intravenous forms. The mechanism of action is via smooth muscle relaxation and subsequent reduction in bronchospasm. Salbutamol is an extensively used, wellestablished treatment with an established safety profile which is also licensed for tocolysis in premature labour. 6 How the intervention might work Various adrenoreceptor subtypes are present in the human ureter and their utility in the management of ureteral pathology is an area of scientific interest.
The α-adrenoreceptors present in the ureter mediate ureteral contraction; 7 stone passage, as well as reducing the frequency of pain episodes associated with renal colic. 8 There is a body of laboratory evidence that β 2 -adrenoreceptor and β 3 -adrenoreceptor are expressed in the human ureter [9] [10] [11] [12] and that their stimulation mediates ureteral relaxation. [9] [10] [11] [12] [13] It has been demonstrated in animal models that intravenous isoproterenol results in a decrease in ureteral activity. [14] [15] [16] [17] Danuser et al 18 demonstrated that both intravenous and topical isoproterenol reduced the frequency of ureteral contractions to 13% and 31% of controls, respectively. Recently, Jung et al 19 achieved a reduction in renal pelvic pressure using endoluminal isoproterenol during ureterorenoscopic irrigation in human participants.
As yet, there is no direct evidence to inform the use of β-agonists as analgesic adjuncts in the treatment of pain associated with renal colic. It has been hypothesised 20 21 that they may alleviate pain in patients with renal colic via ureteral relaxation mediated through β-adrenoreceptor stimulation. It is also worth noting that some β-agonists (eg, salbutamol) are at least partly excreted, unchanged, in the urine; 22 as such, the potential for systemic and topical action exists.
OBJECTIVES
The primary objective of this systematic review was to determine whether β-agonists are effective analgesics for patients with renal colic. Secondary objectives include identifying any effect that β-agonists may have on length of hospital stay or alternative analgesic requirement. We also sought to determine any effect that the impact of stone presence, size and position, and the degree of hydronephrosis, may have on the efficacy of β-agonists as analgesics. 
Outcomes-primary

METHODS
Protocol and registration
The protocol for this systematic review has been prospectively registered on PROSPERO. It can be found at the following web address: http://www.crd.york.ac.uk/ PROSPERO/display_record.asp?ID=CRD42015016266#. VVNR7tNVhBc
The protocol registration number is CRD42015016266.
Study eligibility criteria
We searched for randomised, quasi-randomised, casecontrol and cohort clinical trials that fulfilled the following criteria: ▸ Patients-human participants with either proven or suspected renal colic ▸ Interventions-β-adrenoreceptor agonists ▸ Comparator-any of: placebo; alternative analgesic regime ▸ Outcomes-any of: level of pain, assessed by any quantitative method; length of hospital stay; analgesic requirement; stone presence, size and position; degree of hydronephrosis Lower level evidence such as case series or expert opinion pieces was not included within this systematic review. The background information discussed above provides adequate justification for considering the use of β-agonists in renal colic; as such, further expert opinion was not felt relevant to the study question. Case series alone would not provide adequate justification for changing practice and as such were excluded from the search results. 'Bibliographic records will be published on DARE and NHS EED until 31st March 2015. NIHR funding to produce DARE and NHS EED ceases at the end of March 2015. However, both databases can be accessed via the CRD website. The HTA database will continue to be produced by CRD for the foreseeable future'.
Information sources
We restricted the results of our search to those involving human participants and those either written in English, with an English abstract or with an English translation provided (due to a lack of available funding for translation services). We did not restrict the date range of the results and incorporated both thesaurus headings and keyword searching.
References and conference abstracts were searched by hand and any suitable papers identified and reviewed.
We 
Study selection
Duplicates were removed using Zotero V.4.0. Citations were imported into Mendeley V.1.13.8 (which was used to manage references for the review); any further duplications reported at this stage were manually verified and merged.
Two investigators independently screened the title, abstract and keywords of every record identified by the search. If either investigator felt a paper merited further review, the full text of the article was examined.
All full-text articles were again reviewed independently by two investigators and assessed for eligibility against the above criteria. Differences in opinion were resolved by discussion; a third investigator would have mediated in the event that any discussions were unsuccessful.
RESULTS
The database searches identified 276 records; a further 13 records were found via alternative sources as detailed above. A total of 256 records remained after the removal of duplicates. Following the screening process, four articles were identified for full-text review: Aronson and Hauben; 26 Erickson and Lieske; 27 Helviz et al; 28 and Reed. 29 Details of the record management process during the review can be seen in figure 1 .
None of the articles reviewed at the full-text stage met any of the inclusion criteria for the systematic review. All had titles that did not allow immediate exclusion and three of the four papers did not have abstracts available for review; however, on full-text review, it was found that none of the above articles were clinical trials. Full details of reasons for exclusion can be seen in table 1.
DISCUSSION
There is a disappointing lack of evidence to inform the use of β-agonists for analgesia in patients with renal colic; no relevant clinical trials were identified despite the broad inclusion criteria applied during the selection process.
There is a clear biological plausibility for the use of β-agonists in renal colic; the available evidence confirms both the presence of β-adrenoreceptors in the human ureter and that their stimulation causes ureteral relaxation. This effect has been demonstrated in vivo, 19 although in a different cohort of patients and for a different indication.
One potential explanation for the paucity of evidence on this topic is the recent research focus on the utility of α-adrenoreceptor antagonists in patients with nephrolithiasis. They have previously been thought to reduce stone transit time and the frequency of pain episodes; 8 the oral formulation and longer duration of action renders them ideal agents for long-term management and has rightly therefore made them a research focus in the past. However, their use in the emergency department for acute pain control is unfortunately limited by the slow onset time and a lack of evidence of any effect on acute pain; clinical trials have not been powered to detect effects on pain in the acute situation. Recently, significant doubts about their efficacy as expulsive therapies have been raised. 30 Conversely, the potential advantages of β-agonists include their rapid onset time (almost immediate when administered either by the nebulised or intravenous route) and the pre-existing familiarity with their use that exists within acute settings. The potential for both systemic and topical action is also clearly advantageous. Despite some concerns raised within the literature, 18 side effects are usually well tolerated 31 (especially in the absence of significant comorbidity) and a patient group has suggested that the most common side effects (tremor, tachycardia and restlessness) are likely to be an acceptable trade-off in return for improved analgesia. 
CONCLUSION
There is no evidence to support or refute the proposed use of β-agonists for analgesia in patients with renal colic.
Further research on this topic has been suggested as long ago as 1975. 32 β-agonists are cheap, readily available and have predictable, manageable and relatively mild side effects. Given the clinical need, the clear biological plausibility, the animal model evidence and the limited but promising human studies (especially Jung et al 19 ), clinical trials investigating the use of β-agonists in the acute setting for renal colic are recommended.
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